Drug Profile
NOV 10
Alternative Names: NOV-10; PCA-062; PCA-pCADLatest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator MorphoSys; Novartis
- Developer Novartis Oncology
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for phase-I development in Solid-tumours in Japan (IV)
- 28 Jun 2021 No recent reports of development identified for phase-I development in Solid-tumours in Singapore (IV)
- 28 Nov 2020 No recent reports of development identified for phase-I development in Solid-tumours in France (IV)